登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>Rituximab >RIB-Y37

Anti-Rituximab Antibody (AY37) (recommended for PK/PD)

抗体来源(Source)

Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab F(ab')2.

亚型(Isotype)

Mouse IgG1/kappa

特异性(Specificity)

Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Rituximab SDS-PAGE

Anti-Rituximab Antibody (AY37) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Rituximab ELISA

Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) at 2 μg/mL, add increasing concentrations of rituximab (10% human serum) and then add Biotinylated Anti-Rituximab Antibody (Cat. No. RIB-BY35) at 1 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/mL.

Protocol

Rituximab ELISA

Demonstration of the specificity of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) to the rituximab.

Protocol

 

活性(Bioactivity)-FACS

Rituximab FACS

FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.019 μg/ml (Routinely tested).

Protocol

 

背景(Background)

Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定